Insights

Day Pitney Attorneys Richard B. Emmons, Ph.D., and Jacob Golan, Ph.D., explore that question in MedTech Insight, examining how intended use, design, and functionality can trigger FDA oversight and why disclaimers alone may fall short.

In an innovation-driven economy, intellectual property (IP) is often the single most valuable asset a high-tech or biotech company owns—frequently worth more than all its tangible assets combined. Sophisticated investors therefore treat IP diligence as key to de-risking a deal.

Day Pitney New York Private Client Partner Carl Merino co-authored the first installment of an article for Trusts & Estates examining changes to how income from controlled foreign corporations (CFCs) is allocated to U.S. shareholders under the One Big Beautiful Bill Act and recently proposed regulations.

The Social Security Administration (SSA) oversees three different programs that provide monthly income to adults with a disability.